Risk of community-acquired pneumonia after acid-suppressive drugs

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 2, Issue 2, 2005, Pages 72-73

  Laheij, R J F ^c   Spechler, S J ^a,b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c NONE

Author keywords

Acid suppressive drugs; H2 receptor antagonists; Pneumonia; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR;

CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; DRUG WITHDRAWAL; DYSPEPSIA; FOLLOW UP; GASTROESOPHAGEAL REFLUX; HUMAN; INCIDENCE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; TREATMENT OUTCOME;

EID: 20344380681     PISSN: 17434378     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpgasthep0093     Document Type: Short Survey

References (5)

1. Laine L et al. (2000) Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 14: 651-668
2. Marcuard SP et al. (1994) Omeprazole therapy causes malabsorption of cyanocobalamin (vitamin B12). Ann Intern Med 120: 211-215
3. Verdu E et al. (1994) Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds. Gut 35: 455-460
4. Driks MR et al. (1987) Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. The role of gastric colonization. N Engl Med 26: 1376-1382
5. Cook D et al. (1998) A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 338: 791-797